ABSTRACT
BACKGROUND There is growing evidence that tDCS in the Dorsolateral Prefrontal Cortex (DLPFC) technique is effective in controlling craving and relapse in ADS patients. Till now the results are inconclusive. Interestingly, the cerebellum is related to impulsive and compulsive behavior which is supported by both structural and functional neuroimaging findings. There are few clinical trials regarding the effect of cerebellar tDCS in ADS.
OBJECTIVE To assess the effect of Prefronto-cerebellar tDCS in reducing craving and relapses in ADS patients.
METHODS The study population will be randomly assigned to either of two groups i.e. Active and Sham tDCS group. The active group will receive 10 sessions over 5 days; 2mA current for 15 minutes. The site of anodal stimulation is 2cm below the Iz (inion) and cathodal stimulation at F3 (left prefrontal) and in the sham group will receive the same except that intensity of the current is 0.2mA. Patients will be assessed for craving at 3-time points.
CONCLUSION It will be helpful in analyzing the effect of stimulating DLPFC as well as the cerebellum which is a potential novel site in reducing craving and relapse in ADS.
HIGHLIGHTS tDCS in ADS is being tried for the last decade mainly focusing on the frontal area. With the current understanding of the role of the cerebellum in regulating impulsive and compulsive behavior, we intend to add the cerebellum as a potential site for neuromodulation in reducing craving and relapse in ADS patients.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Clinical Trial Register India (CTRI) Registration No: CTRI/2021/09/036989. Reference no: REF/2021/05/043836
Funding Statement
We got the Indian Council of Medical Research (ICMR) award for financial support for the PG-Thesis.[(No.3/2/June-2021/PG-Thesis-HRD(34)].ICMR provided Rs.30,000, which we used for buying the electrodes & the rest of Rs.20,000 will be provided after the completion of the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
At the convened meeting of IEC-AIIMS Raipur held on 29.05.2021, the IEC voted to approve the above referenced protocol. letter by IEC Raipur
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion